BIOMAT Database Logo BIOMAT Database Logo

Tumour-specific inhibition of lymphoma growth by an antisense oligodeoxynucleotide. 1990

M E McManaway, and L M Neckers, and S L Loke, and A A al-Nasser, and R L Redner, and B T Shiramizu, and W L Goldschmidts, and B E Huber, and K Bhatia, and I T Magrath
Pediatric Branch, National Cancer Institute, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland 20892.

In a high proportion of Burkitt lymphomas, transcription of the c-myc gene is initiated from a cryptic promoter in the first intron, creating abnormal messenger RNA molecules in which intron sequences, normally spliced out of the nascent transcripts, persist. An antisense oligodeoxynucleotide directed against these intron sequences greatly inhibited the proliferation of Burkitt lymphoma cell lines containing the abnormal transcripts (ST486 and JD38), but not that of cell lines containing normal c-myc transcripts (KK124). Flow cytometry showed a pronounced reduction in intracellular c-myc protein levels in cell lines containing aberrant myc transcripts, but no change in other cellular proteins. Control oligonucleotide did not inhibit c-myc protein expression or growth. These experiments provide evidence that antisense oligonucleotides targeted against tumour-specific, aberrant RNA species could be effective in controlling the proliferation of tumour cells without affecting normal cells.

UI MeSH Term Description Entries
D007438 Introns Sequences of DNA in the genes that are located between the EXONS. They are transcribed along with the exons but are removed from the primary gene transcript by RNA SPLICING to leave mature RNA. Some introns code for separate genes. Intervening Sequences,Sequences, Intervening,Intervening Sequence,Intron,Sequence, Intervening
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D009841 Oligonucleotides Polymers made up of a few (2-20) nucleotides. In molecular genetics, they refer to a short sequence synthesized to match a region where a mutation is known to occur, and then used as a probe (OLIGONUCLEOTIDE PROBES). (Dorland, 28th ed) Oligonucleotide
D009857 Oncogenes Genes whose gain-of-function alterations lead to NEOPLASTIC CELL TRANSFORMATION. They include, for example, genes for activators or stimulators of CELL PROLIFERATION such as growth factors, growth factor receptors, protein kinases, signal transducers, nuclear phosphoproteins, and transcription factors. A prefix of "v-" before oncogene symbols indicates oncogenes captured and transmitted by RETROVIRUSES; the prefix "c-" before the gene symbol of an oncogene indicates it is the cellular homolog (PROTO-ONCOGENES) of a v-oncogene. Transforming Genes,Oncogene,Transforming Gene,Gene, Transforming,Genes, Transforming
D011518 Proto-Oncogene Proteins Products of proto-oncogenes. Normally they do not have oncogenic or transforming properties, but are involved in the regulation or differentiation of cell growth. They often have protein kinase activity. Cellular Proto-Oncogene Proteins,c-onc Proteins,Proto Oncogene Proteins, Cellular,Proto-Oncogene Products, Cellular,Cellular Proto Oncogene Proteins,Cellular Proto-Oncogene Products,Proto Oncogene Products, Cellular,Proto Oncogene Proteins,Proto-Oncogene Proteins, Cellular,c onc Proteins
D002051 Burkitt Lymphoma A form of undifferentiated malignant LYMPHOMA usually found in central Africa, but also reported in other parts of the world. It is commonly manifested as a large osteolytic lesion in the jaw or as an abdominal mass. B-cell antigens are expressed on the immature cells that make up the tumor in virtually all cases of Burkitt lymphoma. The Epstein-Barr virus (HERPESVIRUS 4, HUMAN) has been isolated from Burkitt lymphoma cases in Africa and it is implicated as the causative agent in these cases; however, most non-African cases are EBV-negative. African Lymphoma,Burkitt Cell Leukemia,Burkitt Tumor,Lymphoma, Burkitt,Burkitt Leukemia,Burkitt's Leukemia,Burkitt's Lymphoma,Burkitt's Tumor,Leukemia, Lymphoblastic, Burkitt-Type,Leukemia, Lymphocytic, L3,Lymphocytic Leukemia, L3,Burkitts Leukemia,Burkitts Lymphoma,Burkitts Tumor,L3 Lymphocytic Leukemia,L3 Lymphocytic Leukemias,Leukemia, Burkitt,Leukemia, Burkitt Cell,Leukemia, Burkitt's,Leukemia, L3 Lymphocytic,Lymphoma, African,Lymphoma, Burkitt's,Tumor, Burkitt,Tumor, Burkitt's
D002455 Cell Division The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION. M Phase,Cell Division Phase,Cell Divisions,Division Phase, Cell,Division, Cell,Divisions, Cell,M Phases,Phase, Cell Division,Phase, M,Phases, M
D004273 DNA, Neoplasm DNA present in neoplastic tissue. Neoplasm DNA
D004353 Drug Evaluation, Preclinical Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications. Drug Screening,Evaluation Studies, Drug, Pre-Clinical,Drug Evaluation Studies, Preclinical,Drug Evaluations, Preclinical,Evaluation Studies, Drug, Preclinical,Evaluation, Preclinical Drug,Evaluations, Preclinical Drug,Medicinal Plants Testing, Preclinical,Preclinical Drug Evaluation,Preclinical Drug Evaluations,Drug Screenings,Screening, Drug,Screenings, Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

M E McManaway, and L M Neckers, and S L Loke, and A A al-Nasser, and R L Redner, and B T Shiramizu, and W L Goldschmidts, and B E Huber, and K Bhatia, and I T Magrath
Specific inhibition of IgE antibody production by an antisense oligodeoxynucleotide oligomer (Oligostick).
November 1992, Immunology,
M E McManaway, and L M Neckers, and S L Loke, and A A al-Nasser, and R L Redner, and B T Shiramizu, and W L Goldschmidts, and B E Huber, and K Bhatia, and I T Magrath
Antisense c-myc inhibition of lymphoma growth.
June 1997, Antisense & nucleic acid drug development,
M E McManaway, and L M Neckers, and S L Loke, and A A al-Nasser, and R L Redner, and B T Shiramizu, and W L Goldschmidts, and B E Huber, and K Bhatia, and I T Magrath
[Inhibition of hepatitis C virus by antisense oligodeoxynucleotide in vitro].
August 1997, Zhonghua yi xue za zhi,
M E McManaway, and L M Neckers, and S L Loke, and A A al-Nasser, and R L Redner, and B T Shiramizu, and W L Goldschmidts, and B E Huber, and K Bhatia, and I T Magrath
Inhibition of tumorigenesis by a cytosine-DNA, methyltransferase, antisense oligodeoxynucleotide.
January 1997, Proceedings of the National Academy of Sciences of the United States of America,
M E McManaway, and L M Neckers, and S L Loke, and A A al-Nasser, and R L Redner, and B T Shiramizu, and W L Goldschmidts, and B E Huber, and K Bhatia, and I T Magrath
Enhancement of glioma-specific immunity in mice by "NOBEL", an insulin-like growth factor 1 receptor antisense oligodeoxynucleotide.
April 2015, Cancer immunology, immunotherapy : CII,
M E McManaway, and L M Neckers, and S L Loke, and A A al-Nasser, and R L Redner, and B T Shiramizu, and W L Goldschmidts, and B E Huber, and K Bhatia, and I T Magrath
Inhibition of the rat cytochrome P450 3A2 by an antisense phosphorothioate oligodeoxynucleotide in vivo.
December 1995, The Journal of pharmacology and experimental therapeutics,
M E McManaway, and L M Neckers, and S L Loke, and A A al-Nasser, and R L Redner, and B T Shiramizu, and W L Goldschmidts, and B E Huber, and K Bhatia, and I T Magrath
Inhibition of ubiquitous mitochondrial creatine kinase expression in HeLa cells by an antisense oligodeoxynucleotide.
February 1997, Molecular and cellular biochemistry,
M E McManaway, and L M Neckers, and S L Loke, and A A al-Nasser, and R L Redner, and B T Shiramizu, and W L Goldschmidts, and B E Huber, and K Bhatia, and I T Magrath
Specific antisense RNA inhibition of growth hormone production in differentiated rat pituitary tumour cells.
August 1990, Biochemical and biophysical research communications,
M E McManaway, and L M Neckers, and S L Loke, and A A al-Nasser, and R L Redner, and B T Shiramizu, and W L Goldschmidts, and B E Huber, and K Bhatia, and I T Magrath
[Study on growth inhibition of implanted tumor in nude mice by antisense oligodeoxynucleotide targeting telomerase RNA.].
April 2008, Zhongguo fei ai za zhi = Chinese journal of lung cancer,
M E McManaway, and L M Neckers, and S L Loke, and A A al-Nasser, and R L Redner, and B T Shiramizu, and W L Goldschmidts, and B E Huber, and K Bhatia, and I T Magrath
An antisense EGFR oligodeoxynucleotide enveloped in Lipofectin induces growth inhibition in human malignant gliomas in vitro.
September 1998, Journal of neuro-oncology,
Copied contents to your clipboard!